ADVFN - Advanced Financial Network.
HOME» NASDAQ » M » MYL Stock Price » MYL Stock News

Mylan Inc. Share News

 Mylan Inc. (mm) Stock Price
MYL Stock Price
 Mylan Inc. (mm) Stock Chart
MYL Stock Chart
 Mylan Inc. (mm) Stock News
MYL Stock News
 Mylan Inc. (mm) Company Information
MYL Company Information
 Mylan Inc. (mm) Stock Trades
MYL Stock Trades

US Judge Upholds Validity Of Merck's Vytorin Patent

By Peter Loftus Of DOW JONES NEWSWIRES A federal judge has upheld the validity of a U.S. patent covering Merck & Co.'s (MRK) Vytorin cholesterol-lowering drug, which could stave off competing generic copies for several years. In an opinion released Friday, U.S. District Judge Jose Linares in federal court in Newark, N.J., said a patent for Vytorin was valid and enforceable. Merck, based in Whitehouse Station, N.J., said in a recent regulatory filing it expects its U.S. exclusivity for Vytorin and a related drug, Zetia, to expire in April 2017. Mylan Inc. (MYL) had applied for U.S. Food and Drug Administration approval to sell a generic version of Vytorin before its patent protection expired, arguing that the patent was invalid and unenforceable. Schering-Plough, which was acquired by Merck in 2009, filed a patent-infringement lawsuit against Mylan in late 2009, seeking to block Mylan's product. A trial was held in December 2011, leading to Judge Linares's opinion Friday. On a conference call with analysts Friday morning, Merck Chief Executive Kenneth Frazier said he was anticipating a favorable decision. "We believe this is a patent that is valid and enforceable," he said. A Mylan spokeswoman couldn't immediately be reached. Earlier Friday, Merck reported first-quarter Vytorin sales of $444 million and Zetia sales of $614 million. Merck previously reached a settlement of patent litigation for Zetia with generics manufacturer Glenmark Pharmaceuticals. The pact will allow Glenmark to sell generic Zetia in December 2016, subject to final regulatory approval. -By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; peter.loftus@dowjones.com

Stock News for Mylan Inc. (MYL)
DateTimeHeadline
04/04/201416:59:07MARKET SNAPSHOT: U.S. Stocks Sell Off; Nasdaq Drop Worst In 2...
04/04/201415:28:10MARKET SNAPSHOT: Nasdaq Risks Worst Day In 2 Months As High-flyers...
04/04/201412:24:06MARKET SNAPSHOT: U.S. Stocks Turn Lower; Nasdaq Down 1.4%
04/04/201411:15:12MARKET SNAPSHOT: U.S. Stocks Edge Higher On Steady Jobs Growth
04/04/201411:11:18MARKET SNAPSHOT: U.S. Stocks Edge Higher; Dow Hits Intraday Record
03/27/201409:44:41U.S. Hot Stocks: Hot Stocks to Watch
03/27/201408:30:40Mylan Says It Won Contract-Breach Case Against GlaxoSmithKline
03/24/201416:56:39MARKET SNAPSHOT: U.S. Stocks Fall; Nasdaq Skids 1.2%
03/24/201415:34:51MARKET SNAPSHOT: Stocks Fall; Nasdaq Set For Biggest Loss In...
03/13/201407:23:08Mylan Plans to Start Selling Generic Celebrex in May
02/27/201416:39:15MARKET SNAPSHOT: U.S. Stock Gains Push S&P 500 To Record
02/27/201413:13:06MARKET SNAPSHOT: U.S. Stocks Rise; S&P 500 Eyes 1,850 Record
02/27/201410:58:13MARKET SNAPSHOT: U.S. Stocks Volatile; Yellen Speaks Before Senate
02/21/201417:42:43Pfizer Will Resume Shipping Thyroid Drug
01/14/201406:11:37Valeant, Actavis, Mylan Said Interested in Buying Pfizer's Generics...
11/15/201309:10:28Caxton Associates LP 3Q 13F: Holdings As Of Sep 30 -2-
11/15/201309:10:28Caxton Associates LP 3Q 13F: Largest Purchases
11/15/201309:10:27Caxton Associates LP 3Q 13F: Holdings As Of Sep 30
11/15/201308:22:24Janus Capital Management 3Q 13F: Holdings As Of -2-
11/15/201308:22:23Janus Capital Management 3Q 13F: Holdings As Of Sep 30

Mylan Inc. and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad